Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CAGE Bio is a clinical-stage biotech developing topical therapies for dermatological and inflammatory conditions using a proprietary ionic liquid-based drug delivery platform. Their lead asset, a topical JAK inhibitor (tofacitinib), is in Phase 2b trials for moderate to severe atopic dermatitis. The technology enables effective localized treatment with reduced systemic side effects and can deliver both small molecules and biologics through the skin barrier. The company has also initiated development of products for papulopustular rosacea.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Lolas Cage.